Open AccessIMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN CONVENTIONAL RENAL CELL CARCINOMA
Author(s) -
ZAKARIA SAKER,
O Tsintsadze,
T Jorbenadze,
IRMA JIKIA,
L Managadze,
Archil Chkhotua
Publication year - 2022
Publication title -
ek'sperimentuli da klinikuri medic'ina
Language(s) - English
Resource type - Journals
ISSN - 1512-0392
DOI - 10.52340/jecm.2022.725
Subject(s) - renal cell carcinoma , mdm2 , lymph node , kidney cancer , pathological , stage (stratigraphy) , medicine , cancer , apoptosis , pathology , kidney , clinical significance , necrosis , oncology , biology , paleontology , biochemistry
The goal of the current study was to analyze the expression of Bcl-2, MDM2 and Bax in benign and malignant renal tissue samples and assess their possible association with different clinical parameters. Prognostic significance of the markers in recurrence-free and cancer-specific survivals has also been evaluated.Activity of MDM2, Bcl-2 and Bax was evaluated in: 24 normal human kidney tissues resected from the patients of different ages (range: 21-80 years), and in 52 conventional RCC samples. Intensity of the markers’ expression was compared between the groups and correlation was analyzed with different clinical parameters.Activity of anti-apoptotic MDM2 and Bcl-2 was significantly elevated while activity of pro-apoptotic Bax was decreased in RCC as compared with normal kidney tissues. Bax expression was positively correlated with patient age. Significant association has been detected between the evaluated markers and cancer clinical parameters like: tumor stage, grade, lymph node and distant metastases. The markers’ activity was associates with the tumor morphological features, in particular: presence of tumor necrosis and microvascular invasion. Disease recurrence and 5-year patient survival were associated with the markers’ activity. Cox regression analyses have shown that tumor size, pathological stage and grade are the risk factors for disease recurrence and patient death.Expression of MDM2 and Bcl-2 is significantly up-regulated, while Bax is down-regulated in RCC as compared with normal kidney tissue. Intensity of the markers’ activities is associated with the tumor pathological and clinical parameters (stage, grade, lymph node and distant metastases, tumor recurrence and patient survival). Further studies with more patients and longer follow-up will uncover the clinical importance of the evaluated markers in RCC.